Table 2.
Distribution of vaginal bleeding and spotting intensity in transgender men, after initiation of testosterone therapy.
| Vaginal bleeding | |||||
|---|---|---|---|---|---|
| Months | None | Moderate | Mild | Severe | Total vaginal bleeding |
| 3 (n = 262) | 215 (82.1%) | 11 (4.2%) | 26 (9.9%) | 10 (3.8%) | 47 (17.9%) |
| 6 (n = 256) | 234 (91.4%) | 6 (2.3%) | 13 (5.1%) | 3 (1.2%) | 22 (8.6%) |
| 9 (n = 143) | 140 (97.9%) | 1 (0.7%) | 2 (1.4%) | 0 | 3 (2.1%) |
| 12 (n = 234) | 223 (95.3%) | 5 (2.1%) | 6 (2.6%) | 0 | 11 (4.7%) |
| 18–36 (n = 43–101) | 43–101 (100%) | 0 | 0 | 0 | 0 |
| Spotting | |||||
| Months | None | Moderate | Mild | Severe | Total spotting |
| 3 (n = 272) | 199 (73.2%) | 44 (16.2%) | 22 (8.1%) | 7 (2.6%) | 73 (26.8%) |
| 6 (n = 271) | 232 (87.5%) | 18 (6.8%) | 12 (4.5%) | 3 (1.1%) | 33 (12.2%) |
| 9 (n = 145) | 142 (97.9%) | 1 (0.7%) | 1 (0.7%) | 1 (0.7%) | 2 (2.1%) |
| 12 (n = 244) | 227 (93.0%) | 12 (4.9%) | 2 (0.8%) | 3 (1.2%) | 17 (6.9%) |
| 18–36 (n = 43–101) | 43–101 (100%) | 0 | 0 | 0 | 0 |
Frequencies are shown as n (%). The total number of people experiencing vaginal bleeding or spotting are shown in the “total spotting” and “total vaginal bleeding” columns.